$93.85 0.81 (0.87%)
19:59 EDT ABBV Stock Quote Delayed 30 Minutes
Previous Close $93.85
Market Cap 148.93B
PE Ratio 23.58
Volume (Avg. Vol.) 9.63M
Day's Range 92.81 - 95.54
52-Week Range 62.55 - 97.86
Dividend & Yield 3.59 (3.83%)
ABBV Stock Predictions, Articles, and AbbVie News
- From InvestorPlace
- From the Web
AbbVie (ABBV) earnings for the biopharmaceutical company's fourth quarter of 2019 have ABBV stock heading higher on Friday.
These five dividend stocks have total yields equivalent to 8% or more of their market value, making them attractive for investors.
Abbvie stock is a cheap high-yield dividend stock the market overlooks. The Allergan deal, closing shortly, will boost earnings and dividends and push Abbvie stock higher.
Politicians have investors in healthcare stocks nervous as the 2020 election nears. Here's a guide to which firms are good choices and which you should avoid.
Amarin stock has been on fire in 2019, but the reaction to its latest news was discouraging. Is that a buying opportunity or a warning sign?
These dividend stocks yield considerable cash returns, and they will likely produce both payout and stock price increases in the 2020s.
5 cheap high-yield dividend stocks with growing dividends. These five stocks have good dividend growth prospects along with high yields and low price-earnings ratios.
These undervalued stocks have been hit hard lately, but they still have what it takes to make a comeback, making them solid stocks to buy.
5 cheap dividend stocks with high yields and annual increases. These dividend-paying stocks have high yields, low P/E ratios and consistently raise their dividends each year.
General Electric stock has a bearish analyst, while Disney+ already hits 10 million subs. Here's what happened in the stock market today.
With biotech stocks back in favor, investors may selectively pick only those with a deep drug pipeline ahead.
Although recreational weed captures headlines, the real money is on broadly accepted medicinal marijuana stocks.
AbbVie (ABBV) earnings for the biopharmaceutical company's third quarter of 2019 have ABBV stock up Friday on an EPS and revenue beat.
Navellier RatingsPowered by Portfolio Grader